Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces that results from the first-in-human single dose DSR (Direct Sodium Removal) proof-of-concept study for volume overload in heart failure have been selected for oral presentation in the late-breaking abstract session at Heart Failure 2019 on 27 May 2019. Heart Failure 2019 will be held from 25 to 28 May 2019 in Athens, Greece and is the 6th World Congress on Acute Heart Failure organised by the Heart Failure Association of the European Society of Cardiology.

First in Human Experience with Direct Sodium Removal using Zero Sodium Peritoneal Solution: A new candidate therapy for volume overload” will be presented by Dr. Jeffrey Testani, Associate Professor at Yale University.

Session Details:

Name: Late-breaking trial III – Innovative and device therapy

Date: Monday 27 May 2019

Time: 08:30 – 10:00 CEST

Presentation time: 09:30 CEST

Room: Trianti – lecture room (Megaron – Athens International Conference Centre)

Following the oral presentation, the abstract will be available on the website of Sequana Medical and the management team will host a conference call with a live webcast presentation on 27 May 2019 at 14:00 CEST.